期刊
BLOOD
卷 120, 期 16, 页码 3271-3279出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-03-417519
关键词
-
类别
资金
- Regione Piemonte, Ricerca Sanitaria, Ricerca Scientifica e Progetto Strategico ImmOnc
- MIUR, Roma, Italy
- Compagnia San Paolo, Torino, Italy
- FONESA, FOndazione Neoplasie Sangue Onlus, Torino, Italy
- Fondazione CRT, Torino, Italy
- AIRC, Associazione Italiana Ricerca sul Cancro, Milano, Italy
- FISM, Fondazione Italiana Sclerosi Multipla, Genova, Italy
The role of V gamma 9V delta 2 T cells in chronic lymphocytic leukemia (CLL) is unexplored, although these cells have a natural inclination to react against B-cell malignancies. Proliferation induced by zoledronic acid was used as a surrogate of gamma delta TCR-dependent stimulation to functionally interrogate V gamma 9V delta 2 T cells in 106 untreated CLL patients. This assay permitted the identification of responder and low-responder (LR) patients. The LR status was associated with greater baseline counts of V gamma 9V delta 2 T cells and to the expansion of the effector memory and terminally differentiated effector memory subsets. The tumor immunoglobulin heavy chain variable region was more frequently unmutated in CLL cells of LR patients, and the mevalonate pathway, which generates V gamma 9V delta 2 TCR ligands, was more active in unmutated CLL cells. In addition, greater numbers of circulating regulatory T cells were detected in LR patients. In multivariate analysis, the LR condition was an independent predictor of shorter time-to-first treatment. Accordingly, the time-to-first treatment was significantly shorter in patients with greater baseline numbers of total V gamma 9V delta 2 T cells and effector memory and terminally differentiated effector memory subpopulations. These results unveil a clinically relevant in vivo relationship between the mevalonate pathway activity of CLL cells and dysfunctional V beta 9V delta 2 T cells. (Blood. 2012;120(16):3271-3279)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据